Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AFLAC Incorporated (AFL) vs Johnson & Johnson (JNJ) Price & Performance

AFLAC IncorporatedTrade
Johnson & JohnsonTrade

Price performance (Past 24H)

Key statistics

AFLAC Incorporated vs Johnson & Johnson — how do they compare? AFLAC Incorporated trades at $120.87 (market cap $60.70B), while Johnson & Johnson trades at $260.97 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 10.3× AFLAC Incorporated's market cap, and Johnson & Johnson pays the higher dividend (2.06%). Which is the better fit depends on your goals.

AFLJNJ
Market Cap
$60.70B$626.09B
Sector
FinancialsHealth
52-Week High
$129.55$267.24
52-Week Low
$103.55$172.78
Enterprise Value
$70.65B$654.37B
Dividend Yield
2.02%2.06%
Volume
6,156,228

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AFLAC Incorporated

AFL trades at $121.09, down 0.7% on the day, with a bullish overall technical signal but bearish moving averages and oscillators. The stock shows strong profitability with a 26.59% net income margin and 16.91% ROE, though recent quarters have seen EPS misses. Revenue declined to $17.36B in 2025, with net income of $3.65B. Recent news highlights AFL's rebranding of network services and ongoing dividend commitments.

Outlook is mixed; solid fundamentals and a 43-year dividend growth history support income investors, but near-term headwinds include revenue pressure in Japan and FX impacts. Analyst consensus is cautious with a $118 price target below current levels, suggesting limited upside amid execution risks and competitive pressures.

Johnson & Johnson

Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.

Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AFLAC Incorporated

Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.

Read more on AFL

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Read more on JNJ